340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
It's one thing to die from natural causes. Worse, to die from a disease leaked by Chinese scientists in a lab and allowed to wipe out millions. That is now almost certainly the explanation for the origins of COVID-19.
And even worse? U.S. taxpayers paid for it.
The U.S. government hasn't learned a thing. Disease watchers are tracking the spread of H5N1 – bird or avian flu – across the globe as it invades mammals for the first time, leaving South American beaches littered with dead sea lions. In the U.S., 34 dairy cattle herds in nine states are infected.…
